Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focusing on PLK1 inhibition for cancer therapies, has announced its plan to release second quarter 2024 financial results on Thursday, August 8 after market close. The company will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a business update. Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be available in the investor relations section following the event.
Cardiff Oncology (Nasdaq: CRDF), un'azienda biotecnologica in fase clinica focalizzata sull'inibizione di PLK1 per terapie oncologiche, ha annunciato il suo piano di pubblicare i risultati finanziari del secondo trimestre 2024 il giovedì 8 agosto dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una trasmissione web in diretta alle 16:30 ET/13:30 PT lo stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. Le persone interessate possono accedere alla trasmissione web attraverso la sezione 'Investitori' del sito web di Cardiff Oncology. Una registrazione della chiamata sarà disponibile nella sezione relazioni con gli investitori dopo l'evento.
Cardiff Oncology (Nasdaq: CRDF), una empresa de biotecnología en etapa clínica enfocada en la inhibición de PLK1 para terapias contra el cáncer, ha anunciado su plan para publicar los resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto después del cierre del mercado. La empresa realizará una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. ET/1:30 p.m. PT del mismo día para discutir los resultados y proporcionar una actualización comercial. Las partes interesadas pueden acceder a la transmisión a través de la sección 'Inversionistas' en el sitio web de Cardiff Oncology. Una repetición de la llamada estará disponible en la sección de relaciones con inversionistas después del evento.
카디프 온콜로지 (Nasdaq: CRDF)는 암 치료를 위한 PLK1 억제에 집중하는 임상 단계 생명공학 회사로, 2024년 2분기 재무 결과를 8월 8일 목요일 시장 마감 후 발표할 계획을 밝혔습니다. 회사는 같은 날 오후 4시 30분 ET/오후 1시 30분 PT에 결과를 논의하고 사업 업데이트를 제공하기 위한 전화 회의 및 생중계를 개최할 예정입니다. 관심 있는 분들은 카디프 온콜로지 웹사이트의 '투자자' 섹션을 통해 생중계에 접속할 수 있습니다. 이번 이벤트 이후 투자자 관계 섹션에서 통화 재생이 가능합니다.
Cardiff Oncology (Nasdaq: CRDF), une entreprise de biotechnologie en phase clinique axée sur l'inhibition de PLK1 pour les thérapies contre le cancer, a annoncé son plan de publier les résultats financiers du deuxième trimestre 2024 le jeudi 8 août après la clôture du marché. L'entreprise organisera un appel conférence et un webinaire en direct le même jour à 16h30 ET/13h30 PT pour discuter des résultats et fournir une mise à jour sur l'activité. Les parties intéressées peuvent accéder au webinaire par la section 'Investisseurs' du site web de Cardiff Oncology. Un enregistrement de l'appel sera disponible dans la section relations investisseurs après l'événement.
Cardiff Oncology (Nasdaq: CRDF), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf die PLK1-Hemmung zur Krebsbehandlung, hat seinen Plan angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am Donnerstag, den 8. August nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr ET/13:30 Uhr PT eine Telefonkonferenz und einen Live-Webcast abhalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate bereitzustellen. Interessierte können über den Bereich 'Investoren' auf der Website von Cardiff Oncology auf den Webcast zugreifen. Eine Aufzeichnung des Anrufs wird nach der Veranstaltung im Bereich Investor Relations verfügbar sein.
- None.
- None.
- Management will hold a conference call on Thursday, August 8 at 4:30 p.m. ET/1:30 p.m. PT -
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on Thursday, August 8 after the close of trading.
Conference Call and Webcast
Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on August 8, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com
FAQ
When will Cardiff Oncology (CRDF) release its Q2 2024 financial results?
What time is Cardiff Oncology's (CRDF) Q2 2024 earnings call scheduled for?
How can investors access Cardiff Oncology's (CRDF) Q2 2024 earnings call?
Will there be a replay available for Cardiff Oncology's (CRDF) Q2 2024 earnings call?
